CoAxia On Last Legs Following Contested FDA Panel Meeting

CoAxia is out of money in the wake of an unfavorable neurological devices panel meeting about its de novo application for expanded use of its NeuroFlo catheter. The firm says FDA mishandled the meeting, the first public panel meeting for a de novo submission.